Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02035267 · ClinicalTrials.gov registry record · Phase 3
Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat
A Phase 3 study, sponsored by Kythera Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 93
- Enrollment target
NCT02035267 is a Phase 3 study that has completed, run by Kythera Biopharmaceuticals. The registered enrollment target is 93 participants.
The verdict
NCT02035267, a Phase 3 study, has completed, sponsored by Kythera Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 93 participants
- Enrollment target
Study Summary
The objectives of this study are to explore the safety and efficacy of subcutaneous injections of Deoxycholic Acid relative to placebo, in the submental area in patients with mild or extreme fullness of the submental fat and ratings of 1 or 4.
Interventions
- DRUG Placebo
- DRUG Deoxycholic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02035267
The ClinicalTrials.gov registry entry for NCT02035267 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kythera Biopharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02035267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02035267 about?
NCT02035267 is a clinical study titled "Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat". The objectives of this study are to explore the safety and efficacy of subcutaneous injections of Deoxycholic Acid relative to placebo, in the submental area in patients with mild or extreme fullness of the submental fat and ratings of 1 or 4.
What is the current status of trial NCT02035267?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 93 participants. The study started on 2014-01. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02035267?
The interventions under investigation include: Placebo (DRUG), Deoxycholic Acid (DRUG).
Who is sponsoring clinical trial NCT02035267?
This trial is sponsored by Kythera Biopharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.